KPIs & Operating Metrics(New)

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

M (MHO) Asset Writedowns and Impairment (2017 - 2025)

M (MHO) has disclosed Asset Writedowns and Impairment for 10 consecutive years, with $40.1 million as the latest value for Q4 2025.

Quarterly Asset Writedowns and Impairment rose 333.46% to $40.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.7 million through Dec 2025, up 175.82% year-over-year, with the annual reading at $47.7 million for FY2025, 415.68% up from the prior year.
Asset Writedowns and Impairment for Q4 2025 was $40.1 million at M, up from $7.6 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $40.1 million in Q4 2025, with the low at $7.6 million in Q3 2025.